Page 147 - ASHG 2012 Annual Meeting Program Guide

136
POSTER SESSIONS
W=Wednesday authors will present; T=Thursday authors will present; F=Friday authors will present
Hops, N. J. Markward, S. Hall, T. Baker, D. V. Conti, R. F.
Tyndale, N. L. Benowitz, G. E. Swan.
643
T Identification of a SNP in the
UGT1A1
promoter
associated with increased serum bilirubin levels.
M. K.
Kringen, A. P. Piehler, R. M. Grimholt, M. S. Opdal, K. B. F.
Haug, P. Urdal.
644
T Well-characterized cohorts and exome data:
Investigating antipsychotic pharmacogenomics in
the South African context.
B. Drogemoller, D. Niehaus,
G. Wright, B. Chiliza, L. Asmal, L. Koen, R. Emsley, L.
Warnich.
645
T Can genetic variation of CES1A predict
methylphenidate response in ADHD patients?
A. Cassidy, E. Sizer, D. Rutschow, K. Hogg, J. Berg, D.
Coghill.
646
T Whole exome analysis of African American
warfarin pharmacogenomics.
R. Daneshjou, K. Aquino-
Michaels, B. Burkley, L. H. Cavallari, J. A. Johnson, N. A.
Johnson, T. E. Klein, K. J. Karczewski, T. Langaee, S. R.
Patel, M. Perera, H. Sagreiya, H. Tang, N. Tatonetti, R. B.
Altman.
647
T Survey of rare variants in pharmacogenes for
patients with statin-induced myopathy identified in
a biorepository linked to electronic medical records.
M. T. Oetjens, Q. Feng, A. R. Ramirez, E. Bowton, T. Clark,
D. M. Roden, D. C. Crawford, R. A. Wilke.
648
T Genetic determinants of fetal hemoglobin
response to hydroxyurea.
V. A. Sheehan, A. Sabo, J.
R. Crosby, T. A. Howard, D. M. Muzny, B. Davis, A. Li, U.
Nagaswamy, E. Boerwinkle, R. A. Gibbs, R. E. Ware, J. M.
Flannagan.
649
T Translating genetic associations to new
medicines.
M. G. Ehm, S. L. Chissoe, M. R. Nelson, D.
M. Waterworth, L. C. McCarthy, H. Tipney, T. Pastinen, M.
Saleh, P. Gros, P. Agarwal, M. Lathrop, L. R. Cardon, J. B.
Richards, P. Sanseau.
650
T Association of
CYP3A4
and
CYP3A5
genotypes
with treatment-related hyperlipidemy.
L. E. Wong-
Ley, L. E. Figuera, R. Ortiz-Orozco, M. Perez-Nuño,
P. Aguiar-Garcia, F. A. Ortega-Gutierrez, A. Nuñez-
Zenteno.ñ
651
T Pharmacogenetic investigation of diarrhea
in pazopanib-treated patients with renal cell
carcinoma.
Z. Xue, L. Huang, C. N. Sternberg, R. A.
Figlin, L. McCann, C. F. Spraggs, C. Carpenter, L. N.
Pandite, C. Xu.
652
T Multi-ethnic glutathione S-transferase copy
number profiling.
S. Martis, R. Vijzelaar, J. Sload, H. Mei,
L. Edelmann, R. J. Desnick, S. A. Scott.
653
T Pharmacogenomics of cardiovascular disease
treatment in subjects from the Lithuanian population.
A. Pranculis, I. Pepalyte˙ , J. Arasimavicˇ ius, Z. A.
Kucˇ inskiene˙ , V. Kucˇ inskas.
630
T
IL28B
genotypes associated with IFN-induced
virologic response in clinical studies evaluating
eltrombopag treatment in HCV-infected patients with low
platelet counts.
M. Chiano, L. Condreay, L. Briley, D. Pulford,
D. Fraser, K. Johansson, D. Briley, E. Harris, S. Bhatti, D.
Theodore, F. Campbell, S. Vasey, M. Arning, C. Spraggs.
631
T Mapping the incidentalome: Quantifying
incidental findings generated through a clinical
pharmacogenomics project.
K. B. Brothers, M. J.
Westbrook, M. F. Wright, S. L. Van Driest, T. L. McGregor,
J. C. Denny, R. L. Zuvich, E. W. Clayton.
632
T The Coriell Personalized Medicine Collaborative
pharmacogenomics appraisal and evidence scoring
sytem.
N. Gharani, M. A. Keller, C. A. Stack, T. J.
Schmidlen, R. S. Kasper, J. P. Jarvis, N. P. Gerry, E. S.
Gordon, M. F. Christman.
633
T PharmGKB: From pharmacogenomics knowledge
to clinical interpretation and implementation.
L. Gong,
M. Whirl-Carrillo, J. M. Hebert, E. M. McDonagh, K.
Sangkuhl, C. F. Thorn, D. Klein, R. B. Altman, T. E. Klein.
634
T Development of a scoring tool to prioritize clinical
pharmacogenomic testing.
S. F. Manzi.
635
T Pharmacogenomic research undertaken by
PharmGKB consortia groups.
E. M. McDonagh, M. Whirl
Carrillo, L. Gong, J. M. Hebert, K. Sangkuhl, C. F. Thorn,
D. Klein, R. B. Altman, T. E. Klein.
636
T Effects of
CYP2C9
and
VKORC1
polymorphisms
on clinical outcomes and warfarin response: Focusing
on personalized medicine.
P. C. J. L. Santos, R. A. G.
Soares, C. M. C. Strunz, J. E. Krieger, A. C. Pereira.
637
T Performance of a biomarker risk algorithm for a
primary prevention trial of Alzheimer’s disease.
M. W.
Lutz, D. K. Burns, D. G. Crenshaw, A. M. Saunders, A. D.
Roses.
638
T A study of asthma pharmacogenomics using RNA-
seq.
B. E. Himes, R. Hu, P. Wagner, D. Chan, B. Klanderman,
R. A. Panettieri Jr., K. Tantisira, S. T. Weiss, Q. Lu.
639
T Genetic moderators of treatment response
to methylphenidate and guanfacine in children and
adolescents with ADHD.
E. L. Nurmi, K. S. Mallya, F.
Whelan, C. P. Laughlin, J. J. McGough, S. K. Loo, R. M.
Bilder, J. T. McCracken.
640
T Identifying genes that influence acute ethanol
responsive behaviors in
Caenorhabditis elegans
.
J. T.
Alaimo, A. G. Davies, J. C. Bettinger.
641
T Characterization of Northeast Asian ADME gene
variation via exome sequencing.
D. H. Hovelson, Z. Xue,
S. Rashkin, X. Zhan, M. G. Ehm, A. Yeo, I. J. Jang, I. Ieiri,
J. E. Lee, L. R. Cardon, S. L. Chissoe, G. Abecasis, M. R.
Nelson.
642
T Drug metabolizing enzyme genes and nicotine
and cotinine metabolism.
A. W. Bergen, H. S. Javitz, M.
Michel, R. Krasnow, D. Nishita, C. N. Lessov-Schlaggar, H.